ESA treatment in MDS
In this course the schema of administration of ESA will be presented. The predictive factors of response and the outcome of treatment with ESA will also be highlighted and finally what to do after ESA failure will also be discussed.
Hypomethylating agents in MDS
In this course Azacitidine and decitabine treatments in MDS will be discussed. The prognostic factors of response and survival as well as alternative schedules and treatment duration will be explained. Combination of HMAs with other drugs/randomized trials will also be discussed and finally HMAs in lower-risk MDS and before and after ASCT will be presented.
Iron chelation and BSC in MDS
The main objective of this course is to present and explain use of best supportive care (BSC) and iron chelation treatment (ICT) in MDS patients within the framework of other treatment options.
Allogenic Stem Cell Transplantation in MDS
In this course suitable patients for alloBSCT on the basis of disease- and patient specific characteristics will be identified. The prognostic factors without and with alloBSCT will be highlighted. Moreover the different approaches to deal with the time between diagnosis and transplant as well as transplant techniques that may have an influence on treatment results will be discussed. A short overview on post-transplant follow up procedures, minimal residual disease monitoring and the treatment of relapse will also be given.
After completing this course you will be able to understand the recent developments in the pathobiology, clinical, and treatment of myelodysplastic syndrome (MDS) with chromosome 5q deletion (del (5q) as well as understand the long term benefits of treatment, and strategies upon treatment failure.
The objectives of this course are to understand the role of thrombopoietin-receptor agonists in MDS. The risks and benefits of romiplostim and eltrombopag in lower and higher risk MDS will be presented.